NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Equipment

Equipment

6 Months Ended

Mar. 31, 2022

Equipment

Equipment

4. Equipment

The Company’s equipment consisted of the following:


	As of March 31,		As of September 30,
	2022		2021
Laboratory equipment	$	3,065,478	$	2,737,390
Office equipment		259,978		259,978
Leasehold improvements		10,128		—
Total		3,335,584		2,997,368
Accumulated depreciation		(905,852)		(533,486)
Property, plant and equipment, net	$	2,429,732	$	2,463,882

Depreciation expense for the three months ended March 31, 2022 and 2021 was approximately $0.2 million and $0.08 million, respectively. Depreciation expense for the six months ended March 31, 2022 and 2021 was approximately $0.4 million and $0.15 million, respectively.